SHENZHEN, CHINA and ROCKVILLE, MD, March 31, 2022 — HighTide Therapeutics, Inc. (“HighTide”), a global, clinical-stage biopharmaceutical company leading the discovery and development of multi-functional drugs with synergistic effects

SHENZHEN, CHINA and ROCKVILLE, MD, February 22, 2022 — HighTide Therapeutics, Inc. (“HighTide”), a clinical-stage biopharmaceutical company developing treatments for chronic liver / gastrointestinal diseases and metabolic disorders

SHENZHEN, CHINA and ROCKVILLE, MD, January 6, 2022 — HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company developing treatments for liver diseases,

SHENZHEN, CHINA and ROCKVILLE, MD,October 28, 2021 —HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company, announced today the publication of multiple abstracts highlighting positive Phase 2 clinical data with HTD180

Phase 2 Data Published Online in Nature Communications

SHENZHEN, CHINA and ROCKVILLE, MD, September 13, 2021 — HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company, announced that the first group of patients have been enrolled and dosed in a PK bridging stu